Zhang Hongying, Zhang Lubo
Center for Perinatal Biology, Department of Physiology & Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Biol Reprod. 2008 Jan;78(1):35-42. doi: 10.1095/biolreprod.107.063479. Epub 2007 Sep 26.
Previously, we demonstrated that activation of protein kinase C (PRKC) enhanced alpha(1)-adrenergic receptor-induced contractions in nonpregnant ovine uterine arteries but inhibited the contractions in pregnant ovine uterine arteries. The present study tested the hypothesis that differential regulation of PRKC isozyme activities contributes to the different effects of phorbol 12, 13-dibutyrate (PDBu) on alpha(1)-adrenergic receptor-mediated contractions between the pregnant and nonpregnant ovine uterine arteries. Phenylephrine-induced contractions of ovine nonpregnant and pregnant uterine arteries were determined in the absence or presence of the PRKC activator PDBu and/or in combination with conventional and novel PRKC isozyme inhibitor GF109203X, PRKC isozyme-selective inhibitory peptides for conventional PRKC, PRKCB1, PRKCB2, and PRKCE. GF109203X produced a concentration-dependent inhibition of phenylephrine-induced contractions in both nonpregnant and pregnant uterine arteries, and it reversed the PDBu-mediated potentiation and inhibition of phenylephrine-induced contractions in nonpregnant and pregnant uterine artieries, respectively. In addition, PRKCB1, PRKCB2, and PRKCE inhibitory peptides blocked the PDBu-mediated responses in both nonpregnant and pregnant uterine arteries. Western blot analysis showed that PDBu induced a membrane translocation of PRKCA, PRKCB1, PRKCB2, and PRKCE in pregnant uterine arteries, and PRKCB1, PRKCB2, and PRKCE in nonpregnant uterine arteries. The results disprove the hypothesis that the dichotomy of PRKC mechanisms in the regulation of alpha(1)-adrenergic receptor-induced contractions in nonpregnant and pregnant uterine arteries is caused by the activation of different PRKC isozymes, and suggest downstream mechanisms of differential subcellular distributions for the distinct functional effects of PRKC isozymes in the adaptation of uterine arteries to pregnancy.
此前,我们证明蛋白激酶C(PRKC)的激活增强了未孕绵羊子宫动脉中α₁-肾上腺素能受体诱导的收缩,但抑制了孕绵羊子宫动脉中的收缩。本研究检验了以下假设:PRKC同工酶活性的差异调节导致佛波醇12,13-二丁酸酯(PDBu)对孕羊和未孕羊子宫动脉中α₁-肾上腺素能受体介导的收缩产生不同影响。在不存在或存在PRKC激活剂PDBu和/或与传统和新型PRKC同工酶抑制剂GF109203X、传统PRKC、PRKCB1、PRKCB2和PRKCE的PRKC同工酶选择性抑制肽联合使用的情况下,测定去氧肾上腺素诱导的未孕和孕绵羊子宫动脉的收缩。GF109203X对去氧肾上腺素诱导的未孕和孕子宫动脉收缩均产生浓度依赖性抑制,并分别逆转了PDBu介导的未孕和孕子宫动脉中去氧肾上腺素诱导收缩的增强和抑制。此外,PRKCB1、PRKCB2和PRKCE抑制肽阻断了未孕和孕子宫动脉中PDBu介导的反应。蛋白质印迹分析表明,PDBu诱导PRKCA、PRKCB1、PRKCB2和PRKCE在孕子宫动脉中以及PRKCB1、PRKCB2和PRKCE在未孕子宫动脉中的膜转位。结果反驳了以下假设:PRKC机制在调节未孕和孕子宫动脉中α₁-肾上腺素能受体诱导的收缩时的二分法是由不同PRKC同工酶的激活引起的,并提示了PRKC同工酶在子宫动脉适应妊娠的不同功能效应中的差异亚细胞分布的下游机制。